Catalyst Event
CSPC Pharmaceutical Group Ltd (1093) · Other
From Akros SCHK HK-Korea Cosmetics Index (ASHKCOS)
3/24/2026, 12:00:00 AM
Announcement of the first patient dosed in a Phase III clinical study for Anbenitamab (KN026) on March 24, 2026; low importance as clinical milestones generally have limited immediate price impact scheduled.
Korean Translation
2026년 3월 24일 안벤이타맙(KN026) 임상 3상 첫 환자 투여가 발표될 예정이며, 임상 단계 진전에 따른 완만한 주가 상승이 예상됨.
Related Recent Events
CSPC Pharmaceutical Group Ltd (1093) · Other
Final dividend of HKD 0.15 per share for FY2025 (total HKD 0.29, +11.5% YoY) with ex-dividend date June 24, 2026; low importance as dividend increases typically result in minor positive price adjustments scheduled.
6/24/2026, 12:00:00 AM
Samsung Biologics Co Ltd (207940) · Earnings Release
Q1 2026 earnings release for April 29, 2026 scheduled. Minimal market impact from the date announcement expected.
4/29/2026, 12:00:00 AM
HLB Co Ltd (028300) · Other
An investor relations (IR) meeting to announce the group's integrated strategy and the progress of major pipelines; low impact anticipated as it is a routine communication event, scheduled.
4/9/2026, 12:00:00 AM
Celltrion Inc (068270) · Other
Cancellation of 9.11 million treasury shares, valued at approximately KRW 1.71 trillion, effective April 1, 2026. This largest-ever cancellation is expected to have a high market impact.
4/1/2026, 12:00:00 AM
Samchundang Pharm Co Ltd (000250) · Other
The 82nd Annual General Meeting of Shareholders on 2026-03-30 is a routine meeting with low expected price impact scheduled.
3/30/2026, 12:00:00 AM
Hanwha Corp (000880) · Other
The ex-dividend date for the 2025 final dividend of 1,100 KRW per common share is scheduled for 2026-03-30; market impact is estimated to be low (>=1%) following typical dividend adjustments, scheduled.
3/30/2026, 12:00:00 AM